Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The influence of YAP/TAZ and TEAD on Small Cell Lung Cancer

EF 2023-24

Résumé
Drug resistance is the major hurdle impeding cancer therapy. One way cancer cells evade therapy is to change identity. For example, lung adenocarcinoma cells (LUAD) convert to highly lethal small cell lung cancer (SCLC). No cell culture model of this conversion exists but it is essential to dissect the underlying mechanisms and to expose new therapeutic nodes. In exciting preliminary work, our lab has uncovered gene manipulations that induce a marker of SCLC in LUAD cells. Here, I will continue that work to test whether other manipulations further aid the conversion. I will first focus on YAP/TAZ, which are switched on in LUAD, where they promote growth, but are switched off in SCLC, where they instead inhibit growth. Thus, I will ask if removing YAP/TAZ facilitates the LUAD-SCLC switch. In LUAD, YAP/TAZ works with the TEAD family of proteins to active genes that drive cell growth. In contrast, we have discovered that in SCLC, TEADs seem to switch off genes that would otherwise alter cell adhesion and block SCLC growth. Moreover, we have identified TEAD partner proteins that could explain this unique behaviour in SCLC. Two of these partners have vital functions in promoting SCLC, placing TEAD at a vital node in the growth of this cancer. I will manipulate these TEAD partners to test whether, as suspected, they control the target gene repertoire and function of TEADs, and thus the growth of SCLC. Overall, I anticipate developing the first in vitro model of LUAD-SCLC switching, and exposing how TEADs and their partners cooperate to promote SCLC growth. Treatment of this deadly cancer has changed very little in 40 years. My work could expose new therapeutic targets and thus has major clinical relevance.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506572
Name
Yim Andrew J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The influence of YAP/TAZ and TEAD on Small Cell Lung Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ascl1; Lineage Switching; Lung Adenocarcinoma; Neuroendocrine Cancers; Rb1; Small Cell Lung Cancer; Tead; Transcriptional Repression; Yap/Taz
Abstract
Drug resistance is the major hurdle impeding cancer therapy. One way cancer cells evade therapy is to change identity. For example, lung adenocarcinoma cells (LUAD) convert to highly lethal small cell lung cancer (SCLC). No cell culture model of this conversion exists but it is essential to dissect the underlying mechanisms and to expose new therapeutic nodes. In exciting preliminary work, our lab has uncovered gene manipulations that induce a marker of SCLC in LUAD cells. Here, I will continue that work to test whether other manipulations further aid the conversion. I will first focus on YAP/TAZ, which are switched on in LUAD, where they promote growth, but are switched off in SCLC, where they instead inhibit growth. Thus, I will ask if removing YAP/TAZ facilitates the LUAD-SCLC switch. In LUAD, YAP/TAZ works with the TEAD family of proteins to active genes that drive cell growth. In contrast, we have discovered that in SCLC, TEADs seem to switch off genes that would otherwise alter cell adhesion and block SCLC growth. Moreover, we have identified TEAD partner proteins that could explain this unique behaviour in SCLC. Two of these partners have vital functions in promoting SCLC, placing TEAD at a vital node in the growth of this cancer. I will manipulate these TEAD partners to test whether, as suspected, they control the target gene repertoire and function of TEADs, and thus the growth of SCLC. Overall, I anticipate developing the first in vitro model of LUAD-SCLC switching, and exposing how TEADs and their partners cooperate to promote SCLC growth. Treatment of this deadly cancer has changed very little in 40 years. My work could expose new therapeutic targets and thus has major clinical relevance.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yim, Andrew J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~